Effects of lipo-prostaglandin E1 on pulmonary hemodynamics and clinical outcomes in patients with pulmonary arterial hypertension.
作者： Jieyan Shen , Ben He , Binyao Wang , None
DOI: 10.1016/S0012-3692(15)50417-0
关键词:
摘要: Objective To determine whether lipid microspheres containing prostaglandin E 1 (lipo-PGE ) improve pulmonary hemodynamics and clinical outcomes in patients with arterial hypertension (PAH) Methods Forty-nine PAH (8 primary hypertension, 21 collagen vascular disease, 20 congenital systemic-to-pulmonary shunts) were randomly classified into a conventional therapy group (n = 22) or receiving lipo-PGE plus drugs group; n 27). Echocardiographic parameters, New York Heart Association (NYHA) functional class, Bruce treadmill test results for exercise capacity recorded before after treatment Results After 2 weeks of (10 μg bid 14 days), there significant improvements the values (± SD) systolic pressure (SPAP) [76.9 ± 27.9 mm Hg vs 66.5 22.8 Hg, p −5 20.2 10.7 dyne·s·cm , achieved reduction SPAP (10.4 10.3 2.2 5.6 0.002) elevation (1.5 0.9 MET 0.6 1.1 MET, 0.018) Conclusion Lipo-PGE can decrease artery increase
sci-hub.se 参考文章(17)
GERALD SIMONNEAU, ROBYN J. BARST, NAZZARENO GALIE, ROBERT NAEIJE, STUART RICH, ROBERT C. BOURGE, ANNE KEOGH, RONALD OUDIZ, ADAANI FROST, SHELMER D. BLACKBURN, JAMES W. CROW, LEWIS J. RUBIN, Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. American Journal of Respiratory and Critical Care Medicine. ,vol. 165, pp. 800- 804 ,(2002) , 10.1164/AJRCCM.165.6.2106079
Sanjay Mehta, Drug therapy for pulmonary arterial hypertension: what's on the menu today? Chest. ,vol. 124, pp. 2045- 2049 ,(2003) , 10.1378/CHEST.124.6.2045
Julian W. STRANGE, John WHARTON, Peter G. PHILLIPS, Martin R. WILKINS, Recent insights into the pathogenesis and therapeutics of pulmonary hypertension. Clinical Science. ,vol. 102, pp. 253- 268 ,(2002) , 10.1042/CS1020253
J.-Y. Shen, Shun-Le Chen, Yi-Xian Wu, R.-Q. Tao, Yue-Ying Gu, Chun-De Bao, Qin Wang, Pulmonary hypertension in systemic lupus erythematosus. Rheumatology International. ,vol. 18, pp. 147- 151 ,(1999) , 10.1007/S002960050074
Timothy M. Winslow, Maxim A. Ossipov, Gary P. Fazio, Jay S. Simonson, Rita F. Redberg, Nelson B. Schiller, Five-year follow-up study of the prevalence and progression of pulmonary hypertension in systemic lupus erythematosus American Heart Journal. ,vol. 129, pp. 510- 515 ,(1995) , 10.1016/0002-8703(95)90278-3
Vallerie V. McLaughlin, Diane E. Genthner, Maureen M. Panella, Stuart Rich, Reduction in Pulmonary Vascular Resistance with Long-Term Epoprostenol (Prostacyclin) Therapy in Primary Pulmonary Hypertension New England Journal of Medicine. ,vol. 338, pp. 273- 277 ,(1998) , 10.1056/NEJM199801293380501
Janet C. Wanstall, Trina K. Jeffery, Recognition and management of pulmonary hypertension Drugs. ,vol. 56, pp. 989- 1007 ,(1998) , 10.2165/00003495-199856060-00004
Sat Sharma, Treatment of Pulmonary Arterial Hypertension: A Step Forward Chest. ,vol. 124, pp. 8- 11 ,(2003) , 10.1378/CHEST.124.1.8
IKUTO YOSHIYA, RYOKO KAWAHARA, JUN TAKEZAWA, NORIO MIKE, SEI FUKUI, MASAJI NISHIMURA, YUTAKA TACHIMORI, NOBUYUKI TAENAKA, Prostaglandin E1 in pulmonary hypertension of collagen disease. Critical Care Medicine. ,vol. 15, pp. 884- 885 ,(1987) , 10.1097/00003246-198709000-00020
Tetsuo Yamaguchi, Lipid microspheres as drug carriers A pharmaceutical point of view Advanced Drug Delivery Reviews. ,vol. 20, pp. 117- 130 ,(1996) , 10.1016/0169-409X(95)00115-N